Like many I’ve gone through periods of frustration with this stock and people can make up their own minds if much of this stems from an ‘all talk and no substance” ceo from time to time. But it has to be noted that it has had its fair share of bad luck of late...the 2019 submission in the midst of tightening EU marking regs...
https://ec.europa.eu/growth/sectors/medical-devices/new-regulations_en
Then marking right in the middle of the the covid storm, challenging to say the least. So that has to be recognised imo. Kenny’s comments are open to interpretation but maybe the 7m to be allocated to US market efforts have to do with...”The breakthrough designation allows for a faster and less costly route to market, with an emphasis on post-marketing rather than pre-marketing clinical data.“We will share the specifics with the market over the next couple of months,” Mr Kenny
You’ve got to admit the latest CR is a pretty acute 180 degree turn from the “no cr required until 2021” quote as of April 17. The 7m in the bank would have been ample for another 6 months at least imo.
EOY Target, page-17
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.58M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 1.0¢ | 0.9¢ | $99.72K | 11.05M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 6025000 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 2885714 | 3 |
View Market Depth
| Last trade - 13.12pm 22/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |